Back to News
Market Impact: 0.2
SL Science Files MDF For Gamma Delta T Exosomes Showing Potential In Brain Cancers
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationCompany Fundamentals
SL Science Holding (SLBT) filed a new Master Drug File (MDF) with the FDA to cover exosomes derived from Gamma Delta T (GDT) cells. The update is regulatory and product-development oriented, likely incremental rather than immediately financial, with limited near-term market impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
SLBT0.15
More News
- Musk says Terrafab chip factory could outperform rivals despite challenges
- Nvidia GPUs are everywhere. Here are the ways companies are accessing them
- Will Warner Bros. kill Skydance — or will David Ellison kill Warner Bros?
- The world needs Ukraine’s grain. Its farmers are running out of reasons to plant
- Cerebras Is About as Big as Nvidia's Data Center Business Was Nearly a Decade Ago. The Similarities Mostly End There.
- How U.S. know-how is fracking Australia into a gas boom, from Texas oilmen to Trump’s energy secretary